The aesthetic medicine market is crowded with proprietary treatment bundles and combination therapies. The most resilient practices, though, are moving away from simply adding more treatments to a single visit. Instead, they’re building aesthetic treatment sequencing protocols around anatomical need, evidence grading, and each patient’s individual trajectory. This month’s clinical evidence gives providers a clearer framework for what belongs in a combination plan, the order it should be delivered in, and which patients are the right candidates.
In this article:
An unnatural, “overfilled” look usually traces back to one mistake: treating a skin-quality problem as a volume problem. Not every facial concern calls for a structural filler.
That distinction is now built into the label. On June 16, Allergan Aesthetics received FDA approval for SKINVIVE by JUVÉDERM for neck appearance, giving providers an on-label hyaluronic acid microdroplet option built for skin quality and neck lines rather than volume. In the pivotal trial, 74.8% of participants showed clinically significant improvement at one month, with 66% still improved at six months. The trial did not study darker skin tone patients, so providers should factor that gap into candidate selection until more data exists.
Injection depth changes the calculus too. An ultrasound-based investigation in Aesthetic Surgery Journal mapped the deep fatty and fascial continuity between the temple and midface, confirming that injected material spreads differently across that boundary. A related clinical review in Facial Plastic Surgery Clinics of North America reinforces the same point from a different angle: biostimulators like CaHA and PLLA work through gradual collagen stimulation, not immediate structural fill, so they belong earlier in a sequencing plan than a same-day volumizer.
Mixing up skin quality and structural support leads to the “overfilled” look. Treating a dermal-quality issue with a high G-prime volumizing filler distorts natural anatomy and light reflection.
For Newcomers: Master basic HA volumization first, but learn to recognize when a patient actually needs skin conditioning, like SKINVIVE, before adding more volume.
For Established Providers: Audit your temple and midface protocols, and make sure you’re applying current ultrasound-based fascial-plane anatomy rather than habit.
A randomized, split-face trial in the Journal of Dermatological Treatment compared radiofrequency microneedling (RFMN) to fractional CO2 laser for atrophic acne scars. Both modalities improved scarring to a similar degree, but RFMN showed faster recovery and a better pigmentary safety profile in that cohort. That gives providers a real basis for choosing RFMN over CO2 laser for patients at higher risk of post-inflammatory hyperpigmentation, particularly Fitzpatrick III-VI skin types, rather than choosing a device on downtime claims alone.
A separate prospective study in the Journal of Cosmetic and Laser Therapy evaluating RFMN for periorbital wrinkles found more variable results, a mean clinical improvement score reflecting inconsistent response, and transient erythema and edema in every patient. Energy-based devices still require precise depth and energy control regardless of which one is selected.
Choosing RFMN over CO2 laser for the right skin types protects patient safety and the practice’s reputation. It also keeps energy-based devices from being treated as an interchangeable commodity, where the nuance of patient selection gets lost.
For Newcomers: Understand that energy-based devices require precise parameter control, balancing depth against energy, to avoid complications.
For Established Providers: Use this data to refine your resurfacing algorithms, particularly for Fitzpatrick III-VI patients where PIH is the primary concern.
Regenerative offerings need an evidence ladder: controlled trials, early science, and commercial hype are not the same tier, and treating them as equivalent invites regulatory and reputational risk.
On the stronger end, a randomized, open-label controlled trial in JPRAS Open followed 40 patients with mild to moderate facial aging, split into a group treated with autologous fibroblast micrografts and a group treated with an HA skin booster. At 12 months, the fibroblast group showed significantly greater wrinkle reduction, better elasticity, and higher satisfaction scores, though tissue handling adds operational complexity most practices haven’t built out yet. On exosomes, a review in the International Journal of Molecular Sciences found real signal on skin rejuvenation but flagged sourcing heterogeneity and a lack of standardization as limits on generalizing the results. Separately, new operational standards in Clinical, Cosmetic and Investigational Dermatology lay out safety and sequencing protocols for tissue-extracted collagen. That’s expert consensus, not comparative clinical trial data, and should be treated as such.
Unsubstantiated regenerative claims expose a practice to regulatory scrutiny and patient dissatisfaction. Being clear about the actual evidence tier manages expectations and builds longer-term trust.
For Newcomers: Do not inject unapproved biologic products. Stick to established, on-label treatments while the regenerative science matures.
For Established Providers: If offering topical exosomes post-microneedling, rigorously vet suppliers for source transparency and lot consistency.
A patient’s trajectory should set the timeline. A single-session, single-modality approach tends to fail patients who are still changing shape.
A June survey of 406 healthcare providers in Dermatologic Surgery identified midface volume loss and skin laxity as the leading concerns among GLP-1 patients, with providers reporting a sharp rise in this patient population. Someone actively losing weight needs a different sequence than someone whose weight has stabilized. Separately, consumer research from Allergan Aesthetics found that patients who complete a multi-area consultation are more likely to treat multiple areas, driven by trust in the provider’s overall plan rather than any single treatment. That’s a case for building structured, multi-visit pathways that sequence biostimulators, energy devices, and HA fillers deliberately, rather than selling a bundle in one visit.
A single-session, single-modality approach fails patients who are still going through rapid anatomical change. Staging across multiple visits lets structural support build sequentially as the body’s physiology keeps shifting.
For Newcomers: Learn to assess whether a patient’s weight is stable before committing to a comprehensive volumization plan.
For Established Providers: Build structured, multi-visit pathways that sequence biostimulators, energy devices, and HA fillers for the GLP-1 demographic.
Duration-tailored neurotoxins are worth watching, though their regulatory status matters more than the marketing right now. On June 23, Health Canada approved Boey (trenibotulinumtoxinE), a rapid-onset, short-duration neurotoxin for glabellar lines, with visible results in as little as eight hours and a duration of roughly two to three weeks. Boey is not yet approved in the U.S.
This Canadian approval signals a future where duration becomes its own counseling variable, which could lower the barrier for patients who’ve been hesitant about neurotoxins.
IAPAM’s Aesthetic Medicine Symposium is designed for physicians, nurse practitioners, and physician assistants who want to add aesthetic services to their practice — or formalize and expand what they are already doing. The program is hands-on, taught by board-certified dermatologists, and held in an actual clinical setting in Scottsdale, Arizona — not a hotel conference room. It covers injectables, lasers, skin treatments, medical weight management, and the business fundamentals of running a profitable aesthetic practice. If you are a licensed provider who is serious about doing this correctly and profitably, the next available dates are September 18–21, 2026 and November 13–16, 2026 in Scottsdale, AZ. Call 1-866-211-6901 with questions.
What is treatment sequencing in aesthetic medicine?
Treatment sequencing is the deliberate ordering of injectables, devices, and regenerative therapies based on a patient’s anatomy, evidence strength, and stage of change, rather than delivering every treatment in one visit.
How do you decide which treatment to do first in a combination plan?
Start with the underlying tissue problem. Skin-quality issues call for microdroplet HA or biostimulators before structural volume is added, and energy-based resurfacing is typically staged around, not stacked onto, filler sessions.
Should biostimulators be done before or after dermal fillers?
Biostimulators like PLLA and CaHA work through gradual collagen synthesis, so they’re generally sequenced earlier, with structural fillers layered in once the collagen response is underway.
How does GLP-1-related weight loss change treatment sequencing?
Patients still losing weight need staged, reassessed protocols rather than a single comprehensive treatment, since midface volume and skin laxity continue to shift until weight stabilizes.
Are exosomes ready to be added to a regenerative sequencing protocol?
Not for injection. Current evidence is promising but limited by sourcing inconsistency, and no exosome product has FDA approval for aesthetic use. Topical use post-microneedling requires careful supplier vetting.
How does device selection affect sequencing for patients with darker skin tones?
Pigmentary risk should drive device choice for Fitzpatrick III-VI patients. RFMN has shown a better pigmentary safety profile than fractional CO2 laser in at least one split-face trial, which matters when sequencing energy-based treatments.
Advance Your Clinical Competence
Build evidence-based sequencing and comprehensive patient assessment skills through the Certified Aesthetic Provider Program, which includes ongoing access to regenerative and longevity medicine content as the evidence base evolves.
Free CME Training
Get instant access to a complete Botox® training module and earn 1 AMA PRA Category 1 CME at no cost. Covers facial anatomy, crow’s feet injection technique, patient consultation, and safety protocols.
Sign up for free access:
No credit card required. Learn more about this training →
References:
Contains: Emerging trends, expert discussions, recommendations, technique comparisons… and more!